公开(公告)号：US11680263B2

公开(公告)日：2023-06-20

申请号：US17227483

申请日：2021-04-12

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Alon Chen ,  Orna Issler

IPC: C12N15/113 ,  C12Q1/6883 ,  C12N15/11 ,  C07H21/02

CPC classification number: C12N15/113 ,  C12N15/111 ,  C12Q1/6883 ,  C12N2310/141 ,  C12N2320/30 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: A method of treating a bipolar disorder in a subject in need thereof is disclosed. The method comprising administering to the subject sa therapeutically effective amount of a miR-135, a precursor thereof or a nucleic acid molecule encoding said miR-135 or said precursor thereof, thereby treating the bipolar disorder. Methods of diagnosing a mood disorder in a human subject and of monitoring treatment of an anti-depressant drug or a medicament for the treatment of a mood disorder are also disclosed.

公开(公告)号：US10125365B2

公开(公告)日：2018-11-13

申请号：US15111539

申请日：2015-02-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Alon Chen ,  Orna Issler

IPC: C07H21/02 ,  C07H21/04 ,  A61K31/70 ,  C12N15/113 ,  C12N15/11 ,  C12Q1/6883 ,  C12N5/00

Abstract: A method of treating a bipolar disorder in a subject in need thereof is disclosed. The method comprising administering to the subject sa therapeutically effective amount of a miR-135, a precursor thereof or a nucleic acid molecule encoding said miR-135 or said precursor thereof, thereby treating the bipolar disorder. Methods of diagnosing a mood disorder in a human subject and of monitoring treatment of an anti-depressant drug or a medicament for the treatment of a mood disorder are also disclosed.

公开(公告)号：US10975373B2

公开(公告)日：2021-04-13

申请号：US16180083

申请日：2018-11-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Alon Chen ,  Orna Issler

IPC: C12N15/11 ,  C12Q1/6883 ,  C12N15/113

Abstract: A method of treating a bipolar disorder in a subject in need thereof is disclosed. The method comprising administering to the subject sa therapeutically effective amount of a miR-135, a precursor thereof or a nucleic acid molecule encoding said miR-135 or said precursor thereof, thereby treating the bipolar disorder. Methods of diagnosing a mood disorder in a human subject and of monitoring treatment of an anti-depressant drug or a medicament for the treatment of a mood disorder are also disclosed.

公开(公告)号：US09901593B2

公开(公告)日：2018-02-27

申请号：US14856697

申请日：2015-09-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Alon Chen ,  Eran Hornstein ,  Orna Issler ,  Sharon Haramati ,  Naama Volk

IPC: C12N15/11 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/113 ,  C12Q1/68 ,  A61K48/00

CPC classification number: A61K31/7105 ,  A61K31/713 ,  A61K48/0058 ,  C12N15/113 ,  C12N2310/141 ,  C12Q1/6883 ,  C12Q2600/178

Abstract: microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided.

公开(公告)号：US12016876B2

公开(公告)日：2024-06-25

申请号：US17734199

申请日：2022-05-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Alon Chen ,  Eran Hornstein ,  Orna Issler ,  Sharon Haramati ,  Naama Volk

IPC: C12N15/11 ,  A61K31/7105 ,  A61K31/713 ,  A61K48/00 ,  C12N15/113 ,  C12Q1/6883

CPC classification number: A61K31/7105 ,  A61K31/713 ,  A61K48/0058 ,  C12N15/113 ,  C12Q1/6883 ,  C12N2310/141 ,  C12Q2600/178

Abstract: microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided.

公开(公告)号：US10238681B2

公开(公告)日：2019-03-26

申请号：US15873998

申请日：2018-01-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Alon Chen ,  Eran Hornstein ,  Orna Issler ,  Sharon Haramati ,  Naama Volk

IPC: C12N15/11 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/113 ,  C12Q1/6883 ,  A61K48/00

Abstract: microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided.